KRAS and cholangiocarcinoma: The presence of such fusion events in KRAS wildtype mPDAC together with increased expression of genes expressed in cholangiocytes, while hypothesis-generating and not conclusive on their own, prompted us to directly investigate the relationship between KRAS wildtype mPDAC and cholangiocarcinoma samples, the latter of which received genome and transcriptome sequencing as part of the POG trial (n = 14; NCT02155621).